SG Americas Securities LLC Decreases Position in LivaNova PLC $LIVN

SG Americas Securities LLC trimmed its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 93.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 13,191 shares of the company’s stock after selling 188,953 shares during the period. SG Americas Securities LLC’s holdings in LivaNova were worth $691,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of LIVN. GAMMA Investing LLC increased its holdings in shares of LivaNova by 182.5% in the second quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock worth $28,000 after buying an additional 407 shares during the period. State of Wyoming bought a new position in LivaNova during the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC increased its stake in LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares during the period. Parallel Advisors LLC lifted its position in LivaNova by 1,312.3% in the second quarter. Parallel Advisors LLC now owns 1,031 shares of the company’s stock valued at $46,000 after purchasing an additional 958 shares during the last quarter. Finally, Strs Ohio bought a new stake in LivaNova in the first quarter valued at approximately $130,000. 97.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

LIVN has been the topic of several recent analyst reports. The Goldman Sachs Group restated a “neutral” rating and issued a $66.00 target price on shares of LivaNova in a report on Friday, January 9th. Mizuho raised their price target on shares of LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Stifel Nicolaus increased their target price on shares of LivaNova from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Finally, Barclays boosted their price target on LivaNova from $58.00 to $67.00 and gave the company an “equal weight” rating in a report on Friday, January 9th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $69.38.

LivaNova Trading Up 0.6%

Shares of LIVN opened at $63.27 on Thursday. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $65.57. The company has a current ratio of 1.33, a quick ratio of 1.12 and a debt-to-equity ratio of 0.30. The firm’s 50-day moving average price is $61.71 and its 200-day moving average price is $55.00. The firm has a market capitalization of $3.46 billion, a price-to-earnings ratio of -15.82 and a beta of 0.97.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.